Semax vs Selank: Differences, Human Studies and Evidence

These sequences are reported in the human-serum enzyme study. Both have seven amino acids and the same final three residues, Pro-Gly-Pro. Shared structure does not make them interchangeable. Acetylated or amidated variants are also different materials and require their own evidence.

The studies below were selected to show the kinds of evidence behind common comparison claims. This is an evidence guide, not a systematic review or a ranking of clinical benefit.

Yes. The 2020 functional-connectivity study included Semax, Selank and placebo groups. The researchers measured resting-state fMRI before and at 5 and 20 minutes after administration, reporting both shared and compound-specific connectivity findings.

That is more informative than comparing unrelated animal experiments, but its endpoint was brain connectivity. It does not tell us which compound is better for everyday concentration or anxiety, and it did not test a Semax-plus-Selank combination. Study size, allocation methods, blinding, observation time and functional endpoints matter before making a comparative benefit claim.

BDNF is a signaling protein involved in neuronal function; TrkB is one of its receptors. The rat hippocampus experiment links Semax exposure to changes in this system. That finding supports a research question. It does not establish that raising BDNF in a particular experiment improves cognition in every context.

GABA is an inhibitory neurotransmitter. The Selank cell study investigated GABA-related gene expression and interactions with other compounds. Its mixed findings call for model-specific interpretation rather than a simple claim that Selank acts like a non-sedating benzodiazepine.

The pathways are not wholly separate. A human-serum experiment found that both peptides inhibited enzymes involved in enkephalin degradation. Enkephalins are endogenous signaling peptides. This is evidence of overlap in that assay, not evidence that the compounds have identical clinical effects.

Start with the actual question and measured outcome. An anxiety-rating scale, a memory task, a stroke disability score and an imaging signal measure different things. A favorable result on one cannot establish superiority on another.

For each paper, record:

The Semax clinical evidence review addresses its human literature in more detail. The broader cognitive-peptide comparison covers other research compounds with separate mechanisms and evidence bases.

Different experimental effects can motivate a combination hypothesis. They do not show that the combination works, that effects add together or that it is safe. The studies reviewed here do not establish those conclusions.

A research design examining an interaction needs appropriate controls, each compound separately and the combination, with the material and endpoint specified in advance. The human imaging comparison evaluated separate groups, so it cannot be used as evidence for a two-compound regimen. No dosing or treatment recommendation follows from this article.

Record the exact sequence, modifications, formulation and study context. A lyophilized research product is not equivalent to a clinical preparation described in a paper, and a purity percentage alone does not answer every material-quality question.

For laboratory procurement, review the current Semax product specifications, Selank product specifications and batch documents in the COA library. The peptide calculator handles concentration arithmetic after experimental inputs have been selected; it does not select a research dose or establish formulation compatibility. Products are supplied for laboratory research, not human or animal administration.